Drug Search Results
More Filters [+]

BAY59-8862

Alternative Names: bay59-8862, bay598862, bay59 8862
Latest Update: 2014-12-23
Latest Update Note: Clinical Trial Update

Product Description

A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called taxanes.

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BAY59-8862

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00044525

P2

Completed

Breast Cancer

2004-02-01

NCT00044538

P2

Completed

Non-Small-Cell Lung Cancer

None

NCT00044551

P2

Completed

Lymphoma, Non-Hodgkin

None

Recent News Events

Date

Type

Title